Are Biopharma Patents Poised on the Post-Grant Chopping Block?

October 2, 2015
Scott E. Kamholz

BioPharm International, BioPharm International-10-15-2015, Volume 2015 eBook, Issue 2

This article examines trends in biopharma post-grant patent review and projects what the future holds in store.

BioPharm International

eBooks Volume 28, Issue 14  

Post-grant review of patents at the Patent Trial and Appeal Board (PTAB) has taken the intellectual property (IP) world by storm. Post-grant reviews allow anyone to challenge the validity of a patent far more quickly and cheaply than has ever before been possible. They have replaced the huge financial drain and business risk of traditional patent litigation with a rapid adjudication system that delivers certainty for a price comparable to a patent license fee.    Read this article and other articles in

BioPharm International

's 2015

eBook.

Related Content:

BioBusiness